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Adeno-associated virus (AAV)-mediated gene therapy is currently being
pursued as a treatment for the monogenic disorder α-1-antitrypsin
(AAT) deficiency. Results from phase I and II studies have shown
relatively stable and dose-dependent increases in transgene-derived
wild-type AAT after local intramuscular vector administration. In
this report we describe the appearance of transgene-specific T-cell
responses in two subjects that were part of the phase II trial. The
patient with the more robust T-cell response, which was associated
with a reduction in transgene expression, was characterized more
thoroughly in this study. We learned that the AAT-specific T cells in
this patient were cytolytic in phenotype, mapped to a peptide in the
endogenous mutant AAT protein that contained a common poly-
morphism not incorporated into the transgene, and were restricted
by a rare HLA class I C alleles present only in this patient. These
human studies illustrate the genetic influence of the endogenous
gene and HLA haplotype on the outcome of gene therapy.
polymorphism | a-1-antitrypsin | gene therapy | adeno-associated virus |
immune response
Recombinant adeno-associated virus (AAV)-mediated genetherapy holds great promise for the treatment of multiple
diseases (1–8). Preclinical mouse studies have demonstrated sus-
tained correction with a relative paucity of transgene-specific
immunity. Even when present, a potent cytotoxic T-cell (CTL)
response was, by itself, insufficient to eliminate transgene ex-
pression without an accompanying inflammatory response (9, 10).
However, successful transgene expression in small animal models
does not always translate to nonhuman primate models and hu-
mans. For example, nonhuman primates injected i.v. with an AAV
vector expressing GFP elicited a transgene-specific T-cell response
that extinguished transgene expression and caused transient
transaminitis, which was not seen in mice injected with a similar
vector (11). In a hemophilia B trial, an increase in hepatic trans-
aminases with a concomitant decrease in transgene expression was
observed in four patients systemically administered with an AAV
vector (12, 13). These and other observations have led to the
hypothesis that capsid and transgene immunity may compromise
the outcomes of AAV gene therapy clinical trials.
AAV gene therapy is currently being pursued as a treatment for
the monogenic disorder α-1-antitrypsin (AAT) deficiency. Results
from phase I and II studies have shown a dose-dependent increase
in wild-type AAT (m-AAT) after local i.m. administration of
AAV1 vectors (14–18). In these studies, AAV capsid-specific
CD4+ and CD8+ T cells with a cytolytic phenotype were detected
in blood following AAV administration. Interestingly, m-AAT
transgene expression was stable in most patients and was associated
with a regulatory T-cell response characterized by increased CD4+
CD25+FOXP3+ cells at the site of vector administration (18).
However, T-cell responses to the AAT transgene were observed in
a more limited number of patients who participated in the phase II
clinical trial (17).
Here, we describe and characterize the AAT-specific immune
responses found in two trial subjects. Our findings demonstrate
the previously underappreciated role of coding sequence poly-
morphisms and HLA genotypes that in one patient triggered
a class I-restricted immune response to the AAT transgene fol-
lowing gene transfer.
Results
The T-Cell Response to AAT Is Multifunctional and Is Mediated by
CD8+ T Cells. The phase II clinical trial consisted of nine subjects
stratified into three dose cohorts, 6e11, 1.9e12, and 6e12 viral ge-
nomes/kg, who were administered AAV1-AAT i.m. Analysis of
AAV1 capsid and AAT transgene immunity by IFN-γ enzyme-
linked immunospot (ELISPOT) assays indicated that all nine sub-
jects developed AAV1 capsid-specific T cells (17), but only two
subjects (305 and 401) developed AAT transgene-specific T cells
(Fig. 1 A and B). None of the subjects had detectable AAV1- or
AAT-specific T cells in blood before vector administration,
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suggesting that these were primary responses. Nonetheless, we
cannot rule out the presence of AAV1- or AAT-specific memory
T cells in lymphoid organs before vector administration and the
induction of an anamnestic response. Of the two subjects with anti-
AAT immunity, subject 305 had a delayed T-cell response to AAT
peptide pool B 3 mo after vector administration. However, the low
magnitude of the response precluded further analysis of this subject.
In contrast, subject 401, who is homozygous for the z-AAT mu-
tation (Glu342Lys), had a sustained and persistent T-cell response
to peptide pool B of AAT. The T-cell response increased soon after
vector administration, peaked at 3 mo (Fig. 1B), and was detected
for more than 1 y. Transgene expression was lower in this subject
than in the other two subjects who received the same dose of vector
(17), as were vector genomes from muscle biopsies (18). AAT ex-
pression before vector administration was 20–30 nM, and the levels
were similar to those observed in other subjects within the same
cohort (17). Deep sequencing of peripheral blood mononuclear
cells (PBMCs) isolated before and 9 mo after gene therapy revealed
an expansion of the T-cell repertoire, although the antigen speci-
ficity of the expanded T-cell subsets could not be identified by this
analysis (SI Text and Fig. S1, and Table S1). Epitope mapping with
overlapping peptide subpools at 2.5 and 3 mo identified a positive
ELISPOT response against peptide DTEEEDFHVDQVTTV (17).
This epitope, hereafter called “peptide 46,” was located at position
202–216 of the mature protein and was flanked by proteasome
cleavage sites identified by in silico analysis using the NetChop
server (Fig. 1C) (19). The epitope is distant from the z-AAT mu-
tation, which is located at position 342 of the AAT protein.
We investigated whether the immune activation of subject 401
to wild-type AAT could be the result of a previously identified
Val213Ala polymorphism found in a minority of wild-type AAT
alleles and in most z-AAT alleles (20). DNA sequencing revealed
that subject 401, who was homozygous for z-AAT, was also
homozygous for the Val213Ala polymorphism that resides in the
portion of the AAT protein that spans the immunodominant
peptide 46 from subject 401 (Fig. 1C and Fig. S2). The existence
of the polymorphism in the immunodominant peptide suggests
but does not prove that it played a role.
Next, we evaluated the robustness of the AAT immune response
in subject 401 by measuring T-cell polyfunctionality (i.e., the ability
to secrete or activate multiple immune modulators). Activated CD8+
T cells secreted multiple cytokines/chemokines, e.g., TNF, IFN-γ,
IL-2, and macrophage inflammatory protein 1α (MIP-1α), and the
degranulation marker CD107a, which is a surrogate for cytotoxic
activity (Fig. 2A). T-cell responses to peptide 46 were dominated
primarily by IFN-γ– and TNF-secreting CD8+ T cells, and more than
half of the activated CD8+ T cells were polyfunctional, coexpressing
at least three of the five evaluated factors (Fig. 2B, pie charts).
Further phenotypic characterization of peptide 46-stimulated CD8+
T cells showed an abundance of cells with the effector T-cell (Teff)
phenotype (CD27−CD45RO−) (Fig. 2B, density plots). The skewing
of the immune response to a Teff phenotype suggests ongoing an-
tigen exposure, as is consistent with the low but persistent m-AAT
expression in blood and in muscle biopsies (17, 18).
The activation profiles of CD4+ T cells were more distinct fol-
lowing stimulation with the AAT peptide library, peptide pool B, or
peptide 46. CD4+ T-cell response to the AAT peptide library was
dominated by the coexpression of IFN-γ and IL-2 in more than half
of the CD4+ T cells (Fig. 2C). In contrast, the response to pool B
was significantly lower and was dominated by cells coexpressing IL-2
and TNF. In both instances, the CD4+ T-cell response was medi-
ated by central memory (Tcm) (CD27+CD45RO+) and effector
memory (Tem) (CD27−CD45RO+) T cells (Fig. 2D). CD4+ T-cell
responses were absent in cells stimulated with peptide 46. Overall,
these data indicate that the response to AAT immunodominant
epitope peptide 46 is dominated by effector CD8+ T cells with
a cytotoxic profile.
We also detected a T-cell response to AAV capsid in subject
401, and we compared this response with two other trial subjects
(306 and 302) who did not develop AAT immune responses.
These studies indicated that capsid T-cell responses are multi-
functional and diverse (SI Text and Fig. S3).
The Importance of HLA Restriction on the Presentation of the
Immunodominant AAT Epitope. The observation that only one tri-
al subject developed a robust T-cell response, although all are
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Fig. 1. Time course of immune response and epitope location. The time course of the T-cell response to AAV1 capsid and AAT transgene in PBMCs from subjects
305 (A) and 401 (B) was analyzed in duplicate by IFN-γ ELISPOT assay using peptide libraries specific for the full-length AAV1 capsid (pools A, B, and C) and the AAT
transgene (pools A and B). The CEF peptide pool was used at each time point as a positive stimulation control. M, month; SFU, spot-forming units; Y, year.
Asterisks indicate a positive response; the hashtag indicates that no sample analysis was available. (C) Full amino acid sequence of the AAT transgene indicating
peptides included in pool A (black) and B (purple), the location of immunodominant epitopes (brown), the location of polymorphisms and z-AATmutations (blue),
and C-terminal cleavage sites for human proteasome (red). Superscript numbers indicate the amino acid position of the mature AAT protein.
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expected to carry the Val213Ala polymorphism (20), suggests a
possible HLA allele restriction. To identify the allele(s) most
likely responsible for presenting the immunodominant epitope,
we HLA-typed all trial subjects and compared the haplotype of
subject 401 with that of the subjects who did not activate T cells
(Table 1). We were looking for a rare HLA allele that segregated
with the development of AAT-specific T cells. In this analysis, any
HLA allele that was found in a subject who did not mount an
AAT-specific T-cell response would be precluded from being re-
sponsible for presenting the immunodominant epitope in subject
401. Of the HLA alleles present in subject 401 (HLA-A*02/03,
HLA-B*35/44, and HLA-C*04/05), HLA-C*04/05 uniquely seg-
regated with the T-cell response in subject 401 (Table 1). Fur-
thermore, we performed a computational HLA class I affinity
prediction for 8- to 12-mer peptides spanning the polymorphic site
for patient 401’s HLA genotype. This analysis revealed a single
8-mer peptide (HVDQVTTV) predicted to bind with high affinity
to HLA-C*05:01; however, no peptides were predicted to bind
with high affinity to HLA-A or -B alleles (Tables S2 and S3). This
result suggests that the polymorphic site generates a high-affinity
neoepitope in patients carrying the HLA-C*05:01 allele.
To test HLA restriction of the dominant AAT epitope, we
devised a strategy using an ex vivo antigen-presentation model.
Individual HLA alleles were transfected into K562 cells, a human
myelogenous cell line lacking endogenous HLA expression, and
these cells subsequently were used to activate subject 401’s AAT-
specific T cells (Fig. 3). Next, transiently transfected cells were im-
mune-stained to monitor cell-surface class I expression. As expected,
HLA staining was absent in K562 cells transfected with a sham
construct, whereas strong cell-surface staining was observed in more
than 50% of K562 cells transiently transfected with HLA-A*02,
HLA-C*04, or HLA-C*05 (Fig. 3). Next, peptide-loaded transfected
cells were used as antigen-presenting cells (APCs) by coculturing
with PBMCs from subject 401. HLA-C*05 K562 cells activated
subject 401’s AAT-specific T cells threefold over unloaded targets
(Fig. 3, Upper Right). Activation was lower when target cells were
transfected with HLA-A*02. Although subject 401 carried two
unique HLA-C alleles, C*04-transfected cells did not activate T cells
and were similar to control mock-transfected cells.
We observed a similar T-cell response when we used our
ex vivo approach for antigen presentation (Fig. 3, Upper Right)
or when we used professional APCs (Fig. 3, Lower Left);
as expected, the magnitude of the response was lower with
nonprofessional APCs.
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Fig. 2. Functional and phenotypic analysis of the AAT transgene-specific T-cell response in PBMCs from subject 401. (A and C ) Functional profile of
cytokine (IFN-γ, TNF, and IL-2), chemokine (MIP-1α), and surface expression of a degranulation factor (CD107a) by CD8+ (A) and CD4+ (C ) T cells from
PBMCs obtained at the 2.5-mo time point following stimulation with AAT peptide library, AAT pool B, or AAT immunodominant peptide 46
DTEEEDFHVDQVTTV. (B and D) Memory phenotype characterization of AAT-specific CD8+ (B) and CD4+ (D) T cells. Naive cells were defined as CD27+
CD45RO−, Tcm cells were defined as CD27+CD45RO+, Tem cells were defined as CD27−CD45RO+, and Teff cells were defined as CD27−CD45RO−. Pie
charts represent the total AAT-specific T-cell response. Each slice indicates the proportion of cells that produce one to five cytokines as indicated by
different colors.
Table 1. HLA haplotyping of the subjects enrolled in the
clinical trial
Subject
HLA class I
A B C
301 02, 29 18, 44 07, 16
302 01, 31 18, 57 06, 07
303 11, 30 13, 13 06, 06
304 03, 29 44, 51 15,16
305 02, 02 35, 50 06, 15
401 02, 03 35, 44 04, 05
306 01, 02 07, 07 07, 07
307 02, 03 08, 45 06, 07
308 NA NA NA
NA, sample not available for HLA typing. Numbers indicate the two alleles
for A, B, and C loci.
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Discussion
The number of AAV clinical trials is increasing significantly, with
vectors being administered for the treatment of a variety of
disorders. Although T-cell responses to AAV capsid have been
described previously (1, 13–15, 21, 22), the activation of cellular
immune responses to the transgene products following AAV
gene therapy has been less of a problem. It is hypothesized that
patients carrying null mutations are at higher risks of mounting
an immune response to the wild-type therapeutic gene product,
because they should lack central and peripheral tolerance to
all T-cell epitopes. Based on this consideration, patients with
null genotypes have been excluded from participating in some
ongoing AAV clinical trials. A corollary of this hypothesis is that
patients with missense mutations are at a lower risk of mount-
ing T-cell responses to the transgene-derived protein product
because they should be tolerant to all epitopes except those in-
volving the mutation.
A detailed analysis of the immune responses elicited in the
AAV1-AAT clinical trial clearly demonstrates the development of
T cells to the wild-type m-AAT transgene product in a subset of
subjects. The subject with the most robust m-AAT T-cell response
had lower transgene expression than the other two subjects in the
same dose-level group, suggesting that the immune response may
have compromised the outcome of the therapy (17). In addition, the
strong AAV-specific T-cell response detected in this subject may
have played a role in lowering transgene expression, although sim-
ilar AAV-specific T-cell responses in the high-dose group did not
compromise transgene expression (17). Interestingly, the immuno-
dominant epitope in AAT was located outside the z-mutation and
occurred in a previously identified polymorphic site.
Why was a T-cell response generated to an epitope spanning a
polymorphic residue but not to the site of the z-mutation? Fur-
thermore, why was this T-cell response present only in one subject?
We believe that the answers to both questions relate to class I
restriction and HLA genotypes. In this regard, the z-AATmutation
occurs in a region not flanked by proteasome cleavage sites, sug-
gesting that it may not be processed efficiently for class I pre-
sentation. Furthermore, based on in silico analyses, none of the
HLA class I alleles present in the research subjects bound effec-
tively to peptides spanning the z-AAT allele. A similar analysis of
the AAT immunodominant epitope revealed proximity to protea-
some cleavage sites and high-affinity binding to a rare HLA-C
allele found only in subject 401. In vitro binding and T-cell acti-
vation studies confirmed HLA-C*05 class I restriction of this
peptide to the T cells of subject 401.
Several mechanisms could explain the generation of T cells
against m-AAT in subject 401. One possibility is that the poly-
morphism could have diminished class I binding relative to
the same peptide from the m-AAT transgene; alternatively, the
polymorphism could affect the actual processing of the peptide
for class I presentation. Either scenario could result in incomplete
deletion of T cells in the thymus to the polymorphic peptide
ending with activation and targeting of T cells to transduced cells
in the periphery. However, in silico analysis failed to reveal dif-
ferential binding of HLA-C*05 to the polymorphic and wild-type
immunodominant peptides, and the Val213Ala change does
not appear to affect proteasome cleavage sites. Thus the in silico
analysis argues against these hypotheses; however, this evidence
is not definitive because nonanchor residues in class I presented
peptides, although not influencing peptide binding, have been
shown to have substantial effects on T-cell responses (23). An-
other possibility is that i.m. injection of AAV1/m-AAT broke
peripheral tolerance to self-reactive T cells by activating local
inflammation at the site of m-AAT expression; this possibility is
consistent with the presence of persistent inflammation at the
injection site (17). In this case the polymorphism is incidental. It
is possible that both mechanisms contributed to the final result.
Gene therapy with AAV vectors could potentially activate an
immune response to both the transgene and the viral capsid. The
interplay of these immune responses may further influence the
outcome of the treatment (24). It is interesting that other subjects
in this trial developed CD8+ and CD4+ T-cell responses to capsid
with a concomitant increase in FoxP3-expressing regulatory T-cell
responses in both peripheral and locally infiltrating T cells (18).
These subjects also demonstrated an exhausted CD8+ T-cell
phenotype in situ, with expression of both PD-1 and PDL-1.
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Fig. 3. HLA restriction of the dominant AAT epitope. Flowchart of the experiment and immunostaining for HLA surface expression in human K562 cells
transfected with HLA-A*02, HLA-C*04, or HLA-C*05 plasmids. The graph at the upper right shows the IFN-γ ELISPOT response at the 2.5-mo time point of subject
401’s PBMCs cocultured with HLA-transfected K562 cells pulsed with AAT immunodominant peptide 46 (DTEEEDFHVDQVTTV) or the CEF peptide pool. The graph
at the lower left shows the IFN-γ ELISPOT response using the same PBMCs but cultured directly with the CEF peptide pool and AAT immunodominant peptide.
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We conclude that the apparent reduction in transgene expres-
sion that developed in subject 401 in this trial was the result of a
class I-restricted T-cell response to a peptide in AAT. This T-cell
response and its consequence were limited to a single patient who
happened to have a rare HLA-C allele that efficiently presented a
peptide from the transgene-derived protein. We suspect that a
polymorphism in the immunodominant peptide of both z-AAT
alleles of subject 401 resulted in a lack of central tolerance that,
combined with vector-induced inflammation, resulted in a robust
T-cell response to vector-transduced cells. This study shows that
HLA genotype and polymorphism play a substantial role in gene
therapy and should be considered in the investigation of transgene
expression in clinical trials. We speculate that class I restriction
may influence the substantial patient-to-patient variability that has
been seen in some of the AAV gene therapy hemophilia trials.
Methods
Clinical Trial. This study was conducted under the Food and Drug Administra-
tion’s Investigational New Drug program with approval from the institutional
review boards and biosafety committees of the University of Massachusetts
Medical School and Cincinnati Children’s Hospital. All procedures and proto-
cols were in accordance with the tenets of the declaration of Helsinki. This
study is registered with ClinicalTrials.gov (NCT01054339). All subjects provided
written informed consent.
IFN-γ ELISPOT Assay. We analyzed IFN-γ released in PBMCs using previously
describedmethods (1). PBMCs were stimulated in duplicate with medium alone,
AAV1, or AAT peptide libraries. The CEF peptide pool [comprising 32 MHC class
I-restricted T-cell epitopes (8–12 amino acids in length) that contain sequences
derived from the human cytomegalovirus, Epstein–Barr virus, and influenza
virus] (Mabtech) served as a positive control, as previously described (25). Pos-
itive ELISPOT counts were defined as >55 spot-forming units per million lym-
phocytes, i.e., values three times over background (25).
Peptide Libraries. We synthesized a peptide library tailored for the full lengths
of the AAT and the AAV1 capsid as 15-mers with 10-aa overlap (Mimotopes).
TheAATpeptide librarywas divided into twopools,A andB, and theAAV virion
peptide 1 (VP1) peptide library was divided into three pools, A, B, and C, as
previously described (14).
Intracellular Cytokine Staining. PBMCs were stimulated with the AAV1 or AAT
peptide libraries or with individual immunodominant AAT peptide 46
(DTEEEDFHVDQVTTV). Reactive T cells were analyzed functionally and
phenotypically using previously described techniques (1). T-cell polyfunctionality
was assessed by simultaneous detection of secreted TNF, CD107a, IL-2, MIP-1α,
and IFN-γ. Cellular phenotypes were evaluated by the expression of the
surface markers(CD3, CD4, CD8, CD27, and CD45RO. Naive T cells were defined
as CD27+CD45RO−, Tcm cells were defined as CD27+CD45RO+, Tem cells were
defined as CD27−CD45RO+, and Teff cells were defined as CD27−CD45RO−.
T-Cell Receptor β Chain Deep-Sequencing Analysis. Deep-sequencing analysis of
the T-cell receptor β (TCRB) chain was performed using patient PBMCs to de-
tect all possible rearranged genomic sequences and to determine T-cell re-
ceptor variable region b (TCR-Vb) use for each clone (Adaptive Biotechnologies)
as described earlier (18).
HLA Haplotypes Analysis. HLA analysis was performed by LabCorp in eight of
nine subjects enrolled in the trial. Samples for HLA typing were not available
from subject 308.
AAT Polymorphism Analysis. DNA was extracted from eight 10-μm paraffin-
embedded muscle tissue sections using a QIAamp DNA formalin-fixed, par-
affin-embedded tissue kit per the manufacturer’s instructions (Qiagen). A
545-bp product was amplified and sequenced (Genewiz) using primers
(forward: ttggatggtcagtttcagca and reverse: agagggctgaggagggtgaa) flanking
exon 3 (26).
Cell Lines and Transfection. K562 cells were a gift from Carl June, University of
Pennsylvania, Philadelphia, PA. Cells were transiently transfected using
Lipofectamine reagent (Invitrogen). We used indirect immunofluorescence
to image transiently transfected K562 cells expressing individual human HLA
using an anti-human MHC class I antibody. Images were collected using a
Nikon inverted microscope.
Computational HLA Class I Affinity Analysis. To identify peptides predicted to
bind MHC class I with high affinity, a sliding window of 8- to-12-mer peptides
centered on the amino acid of interest were generated and ranked for binding
using the Immune Epitope Database and Analysis Resource (27). Peptides with
an IC50 corresponding to a percentile rank of less than one against a stan-
dardized database were classified as high affinity.
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Changes in T-Cell Repertoire Following Vector
Administration
The functional analysis of T cells, which is limited to measurements
of cytokine secretion or activation, does not reveal the complexity
of the host immune response following vector administration. To
understand the breadth of the T-cell response, we longitudinally
probed the repertoire of T-cell receptor (TCR) diversity in subject
401. High-throughput sequencing of the TCR β-chain comple-
mentary determining region 3 was performed on PBMCs isolated
before and 9 mo following vector administration. Briefly, we
characterized TCR diversity from DNA isolated from the equiv-
alent number of cells using next-generation sequencing (Adaptive
Biotechnologies). We analyzed a total of 663,609 productive se-
quences from PBMCs isolated before vector administration and
998,208 productive sequences from PBMCs isolated 9 mo after
vector administration. At both time points roughly 3.8% of the
total sequences were unique clones (Table S1). However, we
identified an increased number of productive sequences and
unique clones from postinjection samples. This finding indicates
an expansion in peripheral blood T-cell clones. For instance, the
number of unique clones in peripheral blood increased by 36%,
from 25,026 preinjection to 39,207 at 9 mo following vector ad-
ministration (Table S1). This difference may reflect normal tem-
poral variations in the peripheral blood TCR repertoire or may
suggest cellular immune responses to persistent transgene ex-
pression. In support of an ongoing adaptive immune response, a
VB7-9 bias was observed in samples collected at 9 mo.
Among the clonotypes, we found the unique sequence
CASSWDSYEQYF at a frequency of 0.63% (Fig. S1), repre-
senting a substantial expansion of this particular clone in periph-
eral blood following vector administration. Similar analysis
performed at the site of vector administration might demonstrate
T-cell trafficking to the source of antigen expression. However,
muscle biopsy was not available from subject 401. Interestingly, a
similar analysis of the T-cell repertoire in another subject enrolled
in the trial (subject 301) demonstrated the presence of unique
high-frequency clones in both blood and muscle following vector
administration (17). Based on this finding, we expected clone
CASSWDSYEQYF identified in the blood from subject 401 to be
present in muscle also.
The T-Cell Response to AAV1 Is Multifunctional and Diverse
We compared the intracellular staining analyses of AAV1 capsid-
specific T-cell responses from subject 401 and from two other trial
subjects (302 and 306) (17) and found that AAV1-specific re-
sponses, although varied in magnitude, had a similar cytokine
profile among subjects. In subject 401, CD8+ T cells predominantly
expressed IFN-γ, TNF, IL-2, and MIP-1α (Fig. S3A) with 14% of
AAV1-specfic CD8+ T cells coexpressing at least three factors
(Fig. S3B, pie chart). Although the CD8+ T-cell response to
AAV1 was similar among the three subjects, there were differ-
ences in the functional profile. The main differences in subjects
306 and 302 were the increased numbers of CD8+ T cells coex-
pressing three factors (80% and 52%, respectively) and the acti-
vation of CD107a (Fig. S3A). Interestingly, we could not detect
the expression of CD107a among the AAV1-specific T cells from
subject 401. Despite these functional differences, the phenotypic
profile of the T cells was similar across subjects with an abundance
of Tcm and Teff cells (Fig. S3B).
CD4+ T-cell responses were similar between subjects 401 and
306, with up-regulation of IFN-γ, IL-2, and TNF (Fig. S3C). Fifty-
nine percent and 80% of CD4+ T cells from subjects 401 and
306, respectively, coexpressed at least two factors (Fig. S3D, pie
charts). The phenotypes of activated CD4+ Tcm and Teff cells
were similar in these subjects (Fig. S3D). AAV1-specfic CD4+
T cells were not activated in subject 302 (Fig. S3C).
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Fig. S1. TCRB-chain deep-sequencing analysis of the number of T-cell clones in blood before (y axis) and after (x axis) gene transfer in subject 401. Green
triangles indicate T-cell clones present before injection. Blue triangles indicate T-cell clones present after injection. Red circles indicate T-cell clones present
both before and after injection.
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Transgene AAT KWERPFEVKDTEEEDFHVDQvTTVKVPMMKRLG
Subject 401 AAT KWERPFEVKDTEEEDFHVDQATTVKVPMMKRLG 
Epitope 202DTEEEDFHVDQvTTV216
Transgene AAT GTG GAC CAG GTG ACC ACC GTG
Subject 401 AAT Exon III   GTG GAC CAG GCG ACC ACC GTG
A
B
Fig. S2. AAT polymorphism. DNA (A) and amino acid (B) sequence alignment from the AAT transgene and from the AAT region of subject 401 in which the
polymorphism was detected. The amino acid sequence of immunodominant epitope peptide 46 is aligned to transgene and subject 401 AAT sequences. The
enlarged letters indicate the specific base and amino acid responsible for the polymorphism and the z-mutation.
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Fig. S3. Functional and phenotypic analysis of the AAV1 capsid-specific T-cell response in PBMCs from subjects 401, 302, and 306. (A and C) Functional profile
of cytokine (IFN-γ, TNF, IL-2), chemokine (MIP-1α), and surface expression of degranulation factor (CD107a) by CD8+ (A) and CD4+ (C) T cells from PBMCs
obtained 2.5 mo following stimulation with the AAV1 peptide library. (B and D) Memory phenotype characterization of AAV1-specific CD8+ (B) and CD4+ (D) T
cells. Naive cells were defined as CD27+CD45RO−, Tcm cells as CD27+CD45RO+, Tem cells as CD27−CD45RO+, and Teff cells as CD27−CD45RO−. Pie charts
represent the total AAV-specific T-cell response; each slice indicates the proportion of cells that produce one to five cytokines, as indicated by different colors.
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